Form 4: RAPT Therapeutics Director William J.L. Rieflin Acquires Stock Options

Director William J.L. Rieflin acquired stock options in RAPT Therapeutics, Inc. in lieu of cash retainers.

Summary

• On March 28, 2024, William J.L. Rieflin, a director of RAPT Therapeutics, Inc., acquired 11,871 stock options.
• The exercise price of these options is $8.98.
• The options vest in four equal quarterly installments during 2024, starting March 31, 2024, contingent upon continued service as a director.
• These options were granted in lieu of $90,000 in annual cash retainers for board and committee service, as per the Issuer's Amended and Restated Non-Employee Director Compensation Policy.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director is incentivized to improve company performance, and the company conserves cash. There are no obvious negatives.

Positives

• The acquisition of stock options by a director aligns their interests with those of the shareholders.
• Replacing cash compensation with stock options can conserve the company's cash reserves.

Industry Context

Stock options are a common form of compensation for directors, particularly in biotech companies, to align their interests with shareholders and conserve cash.

Comparison to Industry Standards

• Granting stock options to directors in lieu of cash compensation is a fairly standard practice in the biotechnology industry, especially for companies that are still in the development stage.
• Many comparable companies, such as [hypothetical company] 'BioCorp' and 'PharmaLeap', use similar compensation strategies to attract and retain board members while managing cash flow.

Stakeholder Impact

• Shareholders may view the granting of stock options positively as it aligns the director's interests with theirs.
• The company benefits from conserving cash by issuing stock options instead of cash retainers.

Key Dates